ESR2 and Alzheimer disease: To study the effect of ERβ activation on AD pathology we treated AppNL−G−F male and female mice with the selective ERβ agonist LY500307 daily through oral gavage (0.35 mg/kg) every other week over 5 weeks, starting at 3 months of age.